ARTICLE | Clinical News
Coenzyme Q10: Phase II
October 21, 2002 7:00 AM UTC
In a placebo-controlled U.S. Phase II trial in 80 patients, those given 1,200 mg/day of coenzyme Q10 (largest dose) had 44% less decline in mental function, motor function and ability to carry out act...